🇺🇸 FDA

Company profile · Sponsor

Addex

Addex Therapeutics

ADXN · NYSE pharma GENEVA, V8, USA
Pipeline
6
Drugs
0
Patents
8

Quick answer

Addex (ADXN) is a pharma company. headquartered in GENEVA, V8, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ADXN
Exchange NYSE
Company type pharma
Headquarters GENEVA, V8, USA
SEC CIK 0001574232

Pipeline (6)

Search pipeline →

  1. Dipraglurant

    Addex

    Parkinson Disease

    phase 3 small molecule terminated

    2 trials

  2. ADX10059

    Addex

    Gastroesophageal Reflux

    phase 2 small molecule completed

    2 trials

  3. ADX10059

    Addex

    Migraine

    phase 2 small molecule terminated

    1 trial

  4. ADX48621

    Addex

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  5. Dipraglurant

    Addex

    Blepharospasm

    phase 2 small molecule completed

    1 trial

  6. ADX48621

    Addex

    Healthy

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 11071729

    1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10071095

    1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9938270

    Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9765091

    Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9737533

    1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9266834

    1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9226930

    1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9132122

    1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Addex?

Addex (ADXN) is a pharma company. headquartered in GENEVA, V8, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Addex sponsor?

We track 6 ClinicalTrials.gov-linked programs for Addex, including Dipraglurant and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Addex company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.